Health Highlights: July 12, 2021Last Updated: July 12, 2021.
By Ernie Mundell HealthDay Reporter
Here's some of HealthDay's top stories for Monday, July 12:
FDA to add Guillain-Barre warning to J&J COVID vaccine. Although cases are extremely rare -- about 100 reported from over 12.8 million shots given -- the nerve disorder known as Guillain-Barre syndrome could be linked to the Johnson & Johnson COVID-19 vaccine. The FDA is expected to add a warning to the shot's labeling this week. Read more
Flu shot might also prevent severe COVID. New research provides evidence that folks who get their flu shots might have lower odds for severe illness should they contract COVID-19. However, scientists cautioned that the flu vaccine shouldn't be seen as a replacement for any COVID shot. Read more
She's helping vaccinated seniors get back out there. It's a common phenomenon: Many seniors still feel hesitant to rejoin society even though they're fully vaccinated. Octogenarian Sandra Banner is finding creative ways to help her peers overcome their fears. Read more
Pfizer to meet with U.S. officials on approval of COVID vaccine booster. Will people's immunity to SARS-CoV-2 fade so much that they'll need a third dose of vaccine? Researchers say the answer is unclear, but on Monday Pfizer will meet with the FDA and other officials to discuss approval of a booster shot. Read more
Some COVID survivors can't regain lost weight. Gastrointestinal symptoms plague about a fifth of people with severe COVID. Now, some who've recovered are having trouble regaining weight lost during their illness. Read more
Adults with ADHD may face heightened risk for physical ills. New research finds that ADHD could bring lifelong added risks for a variety of respiratory, neurological and other illnesses. Genetics might be largely to blame, scientists say. Read more
|Previous: Black Churches Could Be Key to Boosting Vaccination Rates||Next: Some COVID Survivors Can’t Regain Weight Lost During Illness|
Reader comments on this article are listed below. Review our comments policy.